Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.75 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.75 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | UTS2R | Q9UKP6 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6821884 | 0.89 | KEAP1 (0.77) | KEAP1NFE2L2CYP2A6CA2EPHX1 | |
| SCHEMBL1520041 | 0.86 | KEAP1 (1.00) | KEAP1NFE2L2CYP2A6CA2EPHX1 | |
| Hydrochloric Acid SCHEMBL6821885 | 0.84 | KEAP1 (0.97) | KEAP1NFE2L2CYP2A6CA2EPHX1 | |
| SCHEMBL12359753 | 0.84 | KEAP1 (0.75) | KEAP1NFE2L2CYP2A6CA2EPHX1 | |
| SCHEMBL13995271 | 0.84 | KEAP1 (0.69) | KEAP1NFE2L2CYP2A6CA2EPHX1 | |
| SCHEMBL2251923 | 0.83 | KEAP1 (0.73) | KEAP1NFE2L2CYP2A6CA2EPHX1 | |
| SCHEMBL28563290 | 0.81 | CYP2A6 (0.64) | KEAP1NFE2L2CYP2A6CA2EPHX1 | |
| SCHEMBL28564709 | 0.81 | MTNR1A (0.57) | KEAP1NFE2L2CYP2A6CA2MAPT | |
| SCHEMBL31164712 | 0.81 | MTNR1A (0.57) | KEAP1NFE2L2CYP2A6CA2MAPT | |
| SCHEMBL9751552 | 0.81 | CA2 (0.56) | KEAP1NFE2L2CYP2A6CA2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| EP-1377589-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | claimed |
| WO-2002062804-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2002-08-15 | — | — | WO | claimed |
| CN-108264509-B | Substituted benzothieno [2,3-c ] tetrahydropyridine derivatives, preparation method and application thereof | 复旦大学 | 2021-05-04 | — | — | CN | disclosed |
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | ZHANG HAN-CHENG | 2010-09-23 | — | — | US | disclosed |
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | ZHANG HAN-CHENG | 2010-09-23 | — | — | US | disclosed |
| US-7759380-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7759380-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-07-20 | — | — | US | disclosed |
| US-7608634-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| US-7608634-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| EP-1513520-B1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008005368-A2 | PIPERAZINES AS P2X7 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20070213387-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-20070213387-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-20070213386-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-20070213386-A1 | Substituted pyrrolines as kinase inhibitors | ZHANG HAN-CHENG | 2007-09-13 | — | — | US | disclosed |
| US-7232906-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BG) | 2007-06-19 | — | — | US | disclosed |
| US-7232906-B2 | Substituted pyrrolines as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BG) | 2007-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240650-A1 | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS | PRKDC, MAP2K2, TTK | KEAP1 1493/4885NFE2L2 2076/4885CYP2A6 4744/4885 |
| US-20070213387-A1 | Substituted pyrrolines as kinase inhibitors | PRKDC, MAP2K2, TTK | KEAP1 1493/4885NFE2L2 2076/4885CYP2A6 4744/4885 |
| US-20070213386-A1 | Substituted pyrrolines as kinase inhibitors | PRKDC, MAP2K2, TTK | KEAP1 1493/4885NFE2L2 2076/4885CYP2A6 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.